For example, dasatinib, an orally active small-molecule tyrosine kinase inhibitor that has potent inhibitory activity against EphA2 [33], is being evaluated in clinical studies for the treatment of squamous cell carcinoma (ClinicalTrials.gov identifier: NCT00563290), in combination with chemotherapy for endometrial cancer (ClinicalTrials.gov identifier: NCT01440998), in combination with radiotherapy for glioblastoma (ClinicalTrials.gov identifier: NCT00895960), and in combination with bevacizumab for patients with solid tumors (ClinicalTrials.gov identifier: NCT00792545). The gene discussed is EPHA2; the disease is endometrial cancer.